Expanding the clinical and molecular spectrum of PRMT7 mutations: 3 additional patients and review.
Emanuele AgoliniM L DenticiE BellacchioV AlesiF C RadioA TorellaF MusacchiaM TartagliaB DallapiccolaV NigroM C DigilioA NovelliPublished in: Clinical genetics (2018)
Protein arginine methyltransferase 7 (PRMT7) is a member of a family of enzymes that catalyze the transfer of methyl groups from S-adenosyl-l-methionine to nitrogen atoms on arginine residues. Arginine methylation is involved in multiple biological processes, such as signal transduction, mRNA splicing, transcriptional control, DNA repair, and protein translocation. Currently, 7 patients have been described harboring compound heterozygous or homozygous variants in the PRMT7 gene, causing a novel intellectual disability syndrome, known as SBIDDS syndrome (Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures). We report on 3 additional patients from 2 consanguineous families with severe/moderate intellectual disability, short stature, brachydactyly and dysmorphisms. Exome sequencing revealed 2 novel homozygous mutations in PRMT7. Our findings expand the clinical and molecular spectrum of homozygous PRMT7 mutations, associated to the SBIDDS syndrome, showing a possible correlation between the type of mutation and the severity of the phenotype.
Keyphrases
- intellectual disability
- end stage renal disease
- dna repair
- autism spectrum disorder
- ejection fraction
- nitric oxide
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- transcription factor
- gene expression
- dna damage
- dna methylation
- copy number
- amino acid
- patient reported outcomes
- binding protein
- single molecule
- heat stress